RSV-associated (subtypes A and B) disease in adults aged 60 years of age and older. research hub

A Phase III, open-label, randomized, controlled, multi-country study to evaluate the immune response, safety and reactogenicity of RSVPreF3 OA investigational vaccine when co-administered with 20-valent pneumococcal conjugate vaccine (PCV20) in adults aged 60 years and older.

This study is looking at a new vaccine to protect older adults from RSV, a common chest infection. Researchers are checking if this new vaccine works well and is safe when given at the same time as a pneumonia vaccine.